Home > Insider Trading > Filing (0001213900-11-003836)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
838879	Radient Pharmaceuticals Corp	RXPC	Pharmaceutical Preparations (2834)	330413161

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1326903	Ltd Fund Capital Whalehaven	560 Sylvan Avenue Englewood Cliffs NJ 07632		No	No	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2011-07-08	59,000	$0.12	8,838,000	No	4	S	Direct
Common Stock	Disposition	2011-07-11	225,000	$0.11	8,613,000	No	4	S	Direct
Common Stock	Disposition	2011-07-12	905,000	$0.08	7,708,000	No	4	S	Direct
Common Stock	Disposition	2011-07-13	233,000	$0.08	7,475,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	7,475,000	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common	Convertible Notes	$0.18	2011-05-24	2011-09-24	0	0	Direct
Common	Warrants	$0.18	2009-11-30	2016-12-10	188,777	188,777	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2011-09-24	0	0	Direct
2016-12-10	188,777	188,777	Direct

Footnotes

Pursuant to a Settlement Agreement entered into between the Issuer and Whalehaven Capital Fund Limited ("Whalehaven") on May 17, 2011 as amended by an Amendment to Settlement Agreement dated May 23, 2011, the Issuer agreed to issue shares pursuant to Section 3(a)(10) of the Securities Act of 1933 to Whalehaven. Pursuant to publicly available information, the Issuer has 200,000,000 authorized shares of which 174,368,863 shares have already been issued and are outstanding.
Therefore, the Issuer has not more than 25,631,137 additional shares available for issuance from its authorized shares. Whalehaven believes all such shares have been contractually reserved by the Issuer for issuance to persons other than Whalehaven and have not been reserved for Whalehaven. The Issuer has filed a Preliminary Proxy Statement in order to obtain shareholder approval to increase its authorized shares for the issuance of additional shares to Whalehaven.
Furthermore, on July 19, 2011, Whalehaven sent a letter to the Issuer irrevocably relinquishing its right to convert the Promissory Note issued pursuant to the Settlement Agreement into common stock of the Issuer.
Therefore, it is Whalehaven's position that it is not the beneficial owner of any additional shares.
The terms of the Warrants do not permit the Warrants to be exercised if following such exercise, the holder would beneficially own more than 4.99% of the Issuer's outstanding common stock.